Target for Glycemic Control in Type 2 Diabetic Patients on Hemodialysis: Effects of Anemia and Erythropoietin Injection on Hemoglobin A1c

Therapeutic Apheresis and Dialysis - Tập 13 Số 2 - Trang 89-94 - 2009
Takashi Uzu1, Tsuguru Hatta2, Naoko Deji3, Tamani Izumiya3, Hirotaka Ueda3, Itsuko Miyazawa3, Megumi Kanasaki3, Keiji Isshiki3, Toshihiro Nishio4, Tetsuro Arimura5
1Department of Medicine, Shiga University of Medical Science, Shiga, Japan
2Division of Nephrology and Hypertension, Omihachiman Community Medical Center, Omihachiman, Japan
3Department of Medicine, Shiga University of Medical Science
4Seta Clinic, and
5Social Insurance Shiga Hospital, Otsu,

Tóm tắt

AbstractIn hemodialysis (HD) patients the glycated hemoglobin (HbA1c) level may underestimate glycemic control. The aim of this study is to estimate accurate glycemic control in type 2 diabetic patients on HD. Type 2 diabetes patients (N = 87) who had been receiving maintenance HD for at least one year were enrolled. HbA1c and the percentage of glycated albumin relative to total the serum albumin (%GA) were measured in blood samples and the factors that affected the %GA/HbA1c ratio were examined. There were significant and positive correlations between the plasma glucose and either the HbA1c levels (r = 0.539, P < 0.01) or the %GA level (r = 0.520, P < 0.01). No relationship between the serum albumin levels and %GA levels was observed. A weekly dose of erythropoietin (EPO) was positively correlated with the ratio of %GA/HbA1c and hematocrit (Ht) correlated negatively. There was no significant correlation between the %GA/HbA1c level and the EPO dose in patients with Ht ≥ 30%, although a significant correlation was found between those parameters in the Ht < 30% group. The mean of the %GA/HbA1c ratios in patients with Ht ≥ 30%, with Ht < 30% and treated with EPO < 100 IU/kg/week, and with Ht < 30% and treated with EPO ≥ 100 IU/kg/week were 3.41, 3.56 and 4.13, respectively. In HD patients, accurate glycemic control may be estimated as: HbA1c × 1.14 if Ht ≥ 30%; HbA1c × 1.19 if Ht < 30% and treated with low dosages of EPO; and HbA1c × 1.38 if Ht < 30% and treated with high dosages of EPO.

Từ khóa


Tài liệu tham khảo

U.S. Renal Data System, 2005, Excerpts from the United States Renal Data System 2004 annual data report: atlas of end‐stage renal disease in the United States. International Comparisons, Am J Kidney Dis, 45, S216

10.1161/01.CIR.0000095676.90936.80

10.2337/diacare.23.2.176

Mancia G, 2007, 2007 ESH‐ESC practice guidelines for the management of arterial hypertension: ESH‐ESC task force on the management of arterial hypertension, J Hypertens, 25, 1751, 10.1097/HJH.0b013e3282f0580f

10.1681/ASN.2006070772

10.1038/ki.2008.25

10.2337/dc06-0845

10.1089/152091599317585

10.1056/NEJM199309303291401

10.1016/0168-8227(95)01064-K

10.1016/S0140-6736(98)07019-6

10.1016/S0140-6736(98)07037-8

10.1681/ASN.V75780

10.2337/dc07-S077

10.2337/diacare.25.2.275

10.2152/jmi.53.223

10.1093/ndt/gfg054

10.1111/j.1774-9987.2004.00199.x